CBS 2019
CBSMD教育中心
English

充血性心力衰竭

科研文章

荐读文献

Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced Heart Failure With Improved Ejection Fraction-Is it Possible to Escape One’s Past? Reduced Apolipoprotein M and Adverse Outcomes Across the Spectrum of Human Heart Failure The Evolution of β-Blockers in Coronary Artery Disease and Heart Failure (Part 1/5) The Future of Biomarker-Guided Therapy for Heart Failure After the Guiding Evidence-Based Therapy Using Biomarker Intensified Treatment in Heart Failure (GUIDE-IT) Study Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction INTERMACS Profiles and Outcomes Among Non–Inotrope-Dependent Outpatients With Heart Failure and Reduced Ejection Fraction Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study Randomized Evaluation of Heart Failure With Preserved Ejection Fraction Patients With Acute Heart Failure and Dopamine - The ROPA-DOP Trial Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

Original Research2020 Oct 20;33(3):108288.

JOURNAL:Cell Rep. Article Link

Prdm16 Deficiency Leads to Age-Dependent Cardiac Hypertrophy, Adverse Remodeling, Mitochondrial Dysfunction, and Heart Failure

DM Cibi, KW Bi-Lin, MK Singh et al. Keywords: EHMT1/2; Myc; Prdm16; aging; cardiac fibrosis; cardiac hypertrophy; cardiac metabolism; heart failure; mitochondrial defects

Full Text PDF